Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .

vedicitumomab in combination with pyrrolizidine

RC48 in combination with a platinum-based chemotherapeutic agent

RC48 in combination with teraplizumab